Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Other				LYMNHL0014 80057, LYMNHL0014, NCT00185965, NIH, NCT00185965


2.		Phase?/? Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				20 to 80				Other				WEUTC NCT00669292


3.		Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				A8501006 NCT00321815


4.		A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI, Other				200402002 NCT00233506

Last Modified: 8/25/2008 First Published: 7/24/2008


5.		Phase I Study of PADRE-CMV Fusion Peptide Vaccine or Tetanus-CMV Fusion Peptide Vaccine With or Without CpG 7909 Adjuvant in Healthy Participants Who Are Cytomegalovirus-Seropositive or -Seronegative

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 to 55				NCI				CHNMC-03121 03121, NCT00722839

Last Modified: 11/18/2008 First Published: 5/4/2007


6.		Pilot Study of a Peptide Vaccine Comprising MART-1:27-35 Peptide, gp100:209-217 (210M) Peptide, and Tyrosinase Peptide With Sargramostim (GM-CSF) and CpG 7909 Emulsified in Incomplete Freund's Adjuvant in Patients With Unresectable Recurrent Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				PCI-04173 04-173, PCI-IRB-0607048, 7357, NCT00471471

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute